This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Incyte Corporation (INCY)
Morgan Stanley Healthcare Conference Call
September 12, 2012 10:55 am ET
Paul A. Friedman – President and Chief Executive Officer
David C. Hastings – Executive Vice President, Chief Financial Officer
David Friedman – Morgan Stanley & Co. LLC
PresentationDavid Friedman – Morgan Stanley & Co. LLC
All right. I think we will get started here and thanks everyone for joining us. I’m Dave Friedman, one of the Biotech Analyst. And in terms of personal and research disclosures, you can look at morganstanley.com/disclosure. And I’m joined happily up here by the team from Incyte on the far side Dave Hastings, Chief Financial Officer and then on the near side Paul Friedman, and the relation President and CEO.
And we’d look for this to be as interactive as possible, so anyone should please feel free to raise your hand and shout out, and we’ll make sure we can get your questions asked. So thank you both again for joining us and I think we can just jump right in. You guys relatively recently have had a drug approved for a rare blood diseases, and so maybe you can just talk about the drug, the approval and how the commercial roll out has gone so far.
Paul A. Friedman
Sure. So the drug is JAKAFI, generic name ruxolitinib. It is an inhibitor of two kinases, in a family of kinases known as Janus associated kinase. They are JAK1, JAK2, JAK3 and Tyk2, were all related and a family of enzymes. Our compound inhibits JAK1, and JAK2, but not JAK3, and inhibits Tyk2 to a significantly less degree than JAK1 and JAK2.